Slingshot members are tracking this event:

Following preclinical trial, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial—testing combination of PEG PH20 and atezolizumab in treating pancreatic, gastric tumors among others—In the second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
HALO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, Ate Zo Lizumab, Pancreatic Cancer, Gastric Cancer, Pegph20